

PRODUCT-COMMERCIALIZED/VALIDATED

Name	Spec.	DMF	Main Therapeutic Areas
Apalutamide	In house	Available	Prostate cancer
Apixaban	In house	Available	Anticoagulant
Avatrombopag maleate	In house	Available	Antithrombocytopenics
Azilsartan	In house	Available	Antihypertensive
Azilsartan medoxomil potassium	In house	June.2024	Antihypertensive
Brexiprazole	In house	July.2024	Antidepressants
Brivaracetam	In house	Available	Antiepileptic
Cabozantinib malate	In house	Available	Anticancer
Canagliflozin hemihydrate	In house	Available	SGL2 Inhibitor/Antidiabetic
Candesartan cilexetil	USP/CEP	Available	Antihypertensive
Dabigatran etexilate mesylate	In house	Available	Anticoagulant
Dapagliflozin	In house	Available	SGL2 Inhibitor/Antidiabetic
Dapagliflozin free base	In house	Available	Antidiabetic
Edoxaban tosylate monohydrate	In house	Available	Anticoagulant
Elagolix sodium	In house	Available	Pain due to endometriosis
Empagliflozin	In house	Available	SGL2 Inhibitor/Antidiabetic
Enzalutamide	In house	Available	Anticancer
Ezetimibe	USP	Available	Antihypercholesterolemic
Febuxostat	In house	Available	Antihypercholesterolemic,Antigout
Ibrutinib	In house	Available	Anticancer
Irbesartan	USP/CEP	Available	Antihypertensive
Losartan potassium	USP/CEP	Available	Antihypertensive
Montelukast sodium	USP/CEP	Available	Antiasthma
Nicorandil	JP.EP	Available	Anti angina pectoris
Olmesartan medoxomil	USP/CEP	Available	Antihypertensive
Oteseconazole	In house	Available	Antifungal
Pregabalin	In house	Available	Antiepileptic
Relugolix	In house	Available	Endometriosis
Rivaroxaban	CEP	Available	Anticoagulants
Sacubitril Valsartan Sodium	In house	Available	Antihypertensive
Silodosin	JP. In house	Available	Benign prostatic hyperplasia
Sitagliptin hydrochloride monohydrate	In house	Available	Antidiabetic
Sitagliptin phosphate monohydrate	USP/CEP	Available	Antidiabetic
Tafluprost	In house	Available	Antiglaucoma
Telmisartan	USP/CEP	Available	Antihypertensive
Ticagrelor	CEP	Available	Antiplatelet
Valsartan	USP/CEP	Available	Antihypertensive
Vildagliptin	In house	Available	Antidiabetic
Vonoprazan fumarate	In house	Available	Antiulcer

Remark: Products protected by valid patents are not offered for sale in countries where the scales of such products constitutes a patent infringement. Some of the intermediates are available.

PRODUCT-UNDER VALIDATION

Name	Validation Time	DMF Expected Time	Main Therapeutic Areas
Finerenone	Q3,2024	Q4,2024	Diabetic nephropathy
Abemaciclib	Q4,2024	Q1,2025	Anticancer
Bilastine	Q4,2024	Q1,2025	Antihistamine
Mirogabalin besylate	Q4,2024	Q1,2025	Analgesic
Nebivolol hydrochloride	Q4,2024	Q1,2025	Antihypertensive
Vibegron	Q4,2024	Q1,2025	Overactive bladder

PRODUCT-UNDER DEVELOPMENT

Name	Sample	Main Therapeutic Areas	Name	Sample	Main Therapeutic Areas
Aprocitentan**	Available	Antihypertensive	Daprodustat	Available	Antianemics
Elacestrant dihydrochloride**	Available	Anticancer	Iptacopan hydrochloride	Available	Kidney disease
Ribociclib succinate**	Available	Anticancer	Pirtobrutinib	Available	Anticancer
Acalabrutinib*	Available	Anticancer	Rimegepant sulfate	Available	Antimigraine
Alectinib hydrochloride*	Available	Anticancer	Ritlecitinib tosilate	Available	Antialopecia
Bempedoic acid*	Available	Antilipemic	Ruxolitinib phosphate	Available	Antimyelofibrosis
Darolutamide*	Available	Anticancer	Teneligliptin hydrobromide hydrate	Available	Antidiabetic
Resmetirom*	Available	Nonalcoholic steatohepatitis	Ubrogepant	Available	Antimigraine
Upadacitinib*	Available	Antiarthritic	Elizanetant	In July	Antimenopausal
Bexagliflozin	Available	Antidiabetic	Rilzabrutinib	In July	Antiurticaria

Projects with ** or * are on the validation-preparing list

V4 2024